The Role of PD-L1 Testing in Advanced Genitourinary Malignancies

Andrew W Hahn; Deepika Sirohi; Neeraj Agarwal

doi:10.1016/j.euf.2019.03.003

The Role of PD-L1 Testing in Advanced Genitourinary Malignancies

Eur Urol Focus. 2020 Jan 15;6(1):11-13. doi: 10.1016/j.euf.2019.03.003. Epub 2019 Mar 11.

Authors

Andrew W Hahn¹, Deepika Sirohi¹, Neeraj Agarwal²

Affiliations

¹ Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
² Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: [email protected].

PMID: 30872123
DOI: 10.1016/j.euf.2019.03.003

Abstract

In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression should not receive single-agent immune checkpoint inhibition treatment. By contrast, PD-L1 should not be tested in metastatic renal cell carcinoma and platinum-refractory mUC.

MeSH terms

B7-H1 Antigen / analysis*
Biomarkers, Tumor / analysis*
Carcinoma, Transitional Cell / chemistry*
Carcinoma, Transitional Cell / pathology
Humans
Neoplasm Staging
Urogenital Neoplasms / chemistry*
Urogenital Neoplasms / pathology

Substances

B7-H1 Antigen
Biomarkers, Tumor
CD274 protein, human